| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Vogt Frederick G, Director
Received 200,000 shares by exercise or conversion ($1.51M) · Gave up 191,303 shares to cover exercise price or tax ($1.55M) |
| 12 Nov 2026 |
Form 4: Kirby Daniel Gordon, Chief Commercial Officer
Received 10,000 shares by exercise or conversion · Gave up 3,935 shares to cover exercise price or tax ($31.8K) |
| 10 Nov 2026 |
Form 4: Roche Corleen M., Chief Financial Officer
Received 12,500 shares by exercise or conversion · Gave up 5,311 shares to cover exercise price or tax ($42.7K) |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
8-K: Other Events
Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Privat... |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, |
| 29 Oct 2026 |
8-K: Other Events
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) |
| 05 Oct 2026 |
8-K: Other Events
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1 |
| 02 Oct 2026 |
Form 4: Berkowitz Noah, Chief Medical Officer
Granted 135,000 Stock Options (Right to Buy) · Granted 180,000 Restricted Stock Units · Granted 135,000 Performance Stock Units |
| 02 Oct 2026 |
Form 3: Berkowitz Noah, Chief Medical Officer
No securities owned |
| 29 Sep 2026 |
8-K: Other Events
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million |
| 10 Sep 2026 |
Form 4: Vogt Frederick G, Director
Received 15,626 shares by exercise or conversion · Gave up 6,638 shares to cover exercise price or tax ($57.8K) |
| 10 Sep 2026 |
Form 4: Bilinsky Igor, Chief Operating Officer
Received 7,813 shares by exercise or conversion · Gave up 3,976 shares to cover exercise price or tax ($34.6K) |
| 10 Sep 2026 |
Form 4: Puri Raj K., Chief Regulatory Officer
Received 9,766 shares by exercise or conversion · Gave up 4,478 shares to cover exercise price or tax ($39K) |
| 03 Sep 2026 |
Form 4: Vogt Frederick G, Director
Received 41,669 shares by exercise or conversion · Gave up 17,702 shares to cover exercise price or tax ($147K) |
| 03 Sep 2026 |
Form 4: Puri Raj K., Chief Regulatory Officer
Received 5,470 shares by exercise or conversion · Gave up 2,508 shares to cover exercise price or tax ($20.8K) |
| 03 Sep 2026 |
Form 4: Bilinsky Igor, Chief Operating Officer
Received 8,789 shares by exercise or conversion · Gave up 4,472 shares to cover exercise price or tax ($37K) |
| 12 Aug 2026 |
Form 4: Kirby Daniel Gordon, Chief Commercial Officer
Received 10,001 shares by exercise or conversion · Gave up 2,436 shares to cover exercise price or tax ($15.6K) |
| 10 Aug 2026 |
Form 4: Roche Corleen M., Chief Financial Officer
Received 49,995 shares by exercise or conversion · Gave up 21,238 shares to cover exercise price or tax ($132K) |
Loading...